The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Clinical Trial to Investigate the Safety of Repeated Subcutaneous Injections of HER-096, a Novel Candidate for Disease-modifying Therapy in Parkinson’s Disease
Study Rationale: sHER-096 is a novel compound that mimics CDNF, a human neurotrophic factor that has shown neuroprotective and neurorestorative properties in an animal model of Parkinson’s disease (PD...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Therapeutic Development of Novel STING Inhibitors to Treat Parkinson's Disease Neuroinflammation
Study Rationale: Brain inflammation plays an important role in the pathology and progression of Parkinson’s disease (PD). One of the key proteins involved in this inflammatory process is STING...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of the Dual-action Neuroprotective Compound KLS-13019 to Treat Motor Impairment in a Preclinical Model of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is associated with a loss of mitochondrial function and increased inflammation. A dual-action drug candidate, KLS-13019, both protects mitochondria from...
-
Research Grant, 2024Developing a Binding Assay to Detect Toxic Alpha-synuclein Aggregates in Cerebrospinal Fluid and Plasma
Study Rationale: The formation of toxic protein aggregates is an early step in the pathology of several neurodegenerative disorders, including Parkinson’s disease (PD). Using computer simulations, we...
-
, 2022Uncovering Proteomic Alterations in Parkinson’s Disease Using Patient-specific iPSC-derived Brain Cells
Study Rationale: Transgenic small models have been used as gold standard to study human brain diseases, but it is unclear how conclusive and faithfully these models reflect pathophysiological...
-
Spring 2022 RFA: Cellular Phenotyping in Human iPSCS from the PPMI Cohort, 2022Metabolic Phenotyping in PD Dopaminergic Neurons and Neuronal-glial Co-cultures Using High-throughput Single-cell Metabolomics and Lipidomics
Study Rationale: Recent studies have discovered metabolism to be altered in Parkinson’s disease with cells changing their bioenergetic pathways and accumulating metabolite markers. Every cell in our...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.